Europe's Two Clocks: A 28 November Deadline and a Rulebook Rewrite

Medical device manufacturers selling into Europe are used to one regulatory headache at a time. This autumn there are two — and they run on different clocks. On the first clock: an immovable deadline. Legacy devices still being sold on the EU market must be registered in EUDAMED's UDI/Device module by 28 November 2026 — roughly 40 days from today. On the second clock: a structural rewrite. On 14 October, EU Member States backed Ireland's goal of reaching a Council general approach on the MDR/IVDR simplification regulation before the Irish Presidency ends in December 2026 — potentially the biggest change to Europe's device rules since the MDR itself. One is a compliance deadline. The other is a strategy signal. Both matter for market access, and neither can wait.

Clock one: 28 November is a hard stop, not a soft launch

EUDAMED — the European database on medical devices — became mandatory in stages: on 28 May 2026, four modules switched on (Actor registration, UDI/Device registration, Notified Bodies & Certificates, Market surveillance). Voluntary use ended; parallel national processes no longer suffice.

The transition rule is precise. Devices — legacy or MDR/IVDR-compliant — first placed on the market before 28 May 2026, with additional units still being marketed afterwards, must be registered in the UDI/Device module by 28 November 2026. Registration happens once per device identifier (UDI-DI) and covers every unit sharing it, whatever their lot or serial numbers.

• Non-EU manufacturers register through their EU Authorized Representative. Actor registration produces a Single Registration Number (SRN), validated by the competent authority. Without a valid SRN, devices cannot legally be placed on the EU market.
• No remaining sales after May 2026, no registration needed — unless a later vigilance or post-market surveillance action pulls the device back into the system. Exiting a product line does not permanently exit you from EUDAMED.
• Importers and system/procedure-pack producers also need Actor registration where applicable. This is not a manufacturer-only exercise.
• Notified bodies face their own deadline: retrospective registration of pre-existing certificates in the NB/Certificates module by 28 May 2027.

The scale is the real story. A June 2026 analysis of the public EUDAMED database counted 1,292,737 UDI-DI records (extract dated March 2026, analysis by MedDeviceGuide) — and every company that left its backlog to the last weeks of November will be queuing for the same database and the same competent-authority validation at once. Registration counts move daily; check the live public EUDAMED extract for the current figure before planning around it.

The market-access reading is blunt: under Article 29(1) MDR, a device may not be placed on the market unless it has first been registered by the manufacturer with a UDI in the UDI database — a product placed on the market without that step is non-conforming and not lawfully placed on the market. This is not paperwork for its own sake.

Clock two: the simplification regulation moves toward a general approach

While the database deadline ticks, the rulebook is being rewritten. The Commission's simplification proposal, per the European Parliament's research briefing, includes:

• Reduced administrative burden through simplified rules and reporting for manufacturers, distributors and notified bodies;
• Simpler procedures for AI-based medical devices to avoid overlaps with the EU AI Act — one of the dual-compliance knots the industry has flagged for years;
• More proportionate conformity assessment — clearer timelines and definitions, revised classification rules for software devices and accessories, and greater use of real-world evidence;
• Support for innovation: early scientific expert advice and EU-level regulatory sandboxes to test technologies, including AI applications, under supervision before full conformity assessment;
• EU-level coordination plus international reliance: coordinated oversight of notified bodies, harmonised Member State practice, a formal dispute-resolution mechanism — and use of trusted third-country assessments (e.g. via IMDRF) to cut audit duplication.

The political momentum is real. Ireland's health minister has framed the December target around patients and predictability: companies, she said, need to know when, how and how quickly their products will be registered — acknowledging that Europe's attractiveness as a market has weakened. Parliament has demanded this revision since October 2024, citing device shortages, notified-body bottlenecks and SME burden.

Expect friction: some Member States want deeper simplification, others insist patient safety stays at the heart of the text, and one is pushing preferential treatment for EU-established SMEs. A general approach is a Council position, not a final law — trilogue with Parliament still follows.

What market-entry strategy should do now

• Treat 28 November as operational, not legal-only. Audit which UDI-DIs in your portfolio are still being sold, confirm SRNs are in place for every economic operator in the chain — including your EU Authorized Representative and importers — and file EUDAMED submissions before the late-November rush.
• Re-price Europe in your 2027 planning. A December general approach followed by trilogue could shift conformity-assessment timelines, classification logic and AI-device dual compliance within your next product cycle — portfolio decisions made under today's rules may need revisiting.
• Watch the SME provisions. Preferential measures for smaller manufacturers are actively contested in Council — for small and mid-sized makers, the outcome directly sets the cost of EU market access.

Europe spent a decade building the MDR into the world's most demanding device regime — and is now, simultaneously, enforcing its database and negotiating its simplification. For manufacturers, that is not a contradiction to debate. It is a calendar to work.

Sources

• Agence Europe, 15/10/2026 — Coreper I backs goal of a general approach before the end of the Irish Presidency.
• European Parliamentary Research Service briefing — “Medical devices: Simplifying the rules” (2026).
• Osborne Clarke — “EU triggers mandatory Eudamed use for diagnostics and medtech from May 2026”.
• DNV — “EUDAMED mandatory use: What manufacturers need to know”.
• HPRA (Ireland) — “Mandatory Use of EUDAMED modules for medical devices”.
• Deloitte Germany — “A structured path to EUDAMED implementation”.
• MedDeviceGuide — “EUDAMED at Scale: 1.29 Million UDI-DIs” (analysis dated 9 June 2026).
• CMS Law — “EUDAMED: Implementation deadlines and enforcement risks” (Article 29(1) MDR analysis).